The Phase III ENGOT-OV44/First trial delivers a milestone in ovarian cancer research, suggesting immunotherapy could redefine standard of …
The Phase III ENGOT-OV44/First trial delivers a milestone in ovarian cancer research, suggesting immunotherapy could redefine standard of …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
On December 19, the clinical research world turns its attention to psychedelic medicine, with new data, global trial …
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, …
Shanghai-based Excalipoint secures rights to two preclinical T-cell engagers from Lepu Biopharma, aiming to fast-track development for solid …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
From decentralized designs to ethical reform, the NIH Pragmatic Trials Collaboratory closes 2024 with a blueprint for smarter, …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory …